Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib Article Swipe

View

Ondrej Kalous , Dylan Conklin , Amrita Desai , Neil A. O’Brien , Charles Ginther , Lee G. Anderson , David J. Cohen , Carolyn D. Britten , Ian Taylor , James G. Christensen , Dennis J. Slamon , Richard S. Finn ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1158/1535-7163.22499191.v1

PDF file, 55K.

Related Topics

Concepts

Lapatinib Trastuzumab Breast cancer Cancer research Cell growth Cancer cell lines Pharmacology Chemistry Cancer Medicine Internal medicine Cancer cell Biochemistry

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/1535-7163.22499191.v1
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4362533815

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4362533815

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/1535-7163.22499191.v1

Digital Object Identifier
Title: Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-04-03

Full publication date if available
Authors: Ondrej Kalous, Dylan Conklin, Amrita Desai, Neil A. O’Brien, Charles Ginther, Lee G. Anderson, David J. Cohen, Carolyn D. Britten, Ian Taylor, James G. Christensen, Dennis J. Slamon, Richard S. Finn

List of authors in order
Landing page: https://doi.org/10.1158/1535-7163.22499191.v1

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/1535-7163.22499191.v1

Direct OA link when available
Concepts: Lapatinib, Trastuzumab, Breast cancer, Cancer research, Cell growth, Cancer cell lines, Pharmacology, Chemistry, Cancer, Medicine, Internal medicine, Cancer cell, Biochemistry

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4362533815
doi	https://doi.org/10.1158/1535-7163.22499191.v1
ids.doi	https://doi.org/10.1158/1535-7163.22499191.v1
ids.openalex	https://openalex.org/W4362533815
fwci	0.0
type	preprint
title	Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T10755
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9957000017166138
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2730
topics[0].subfield.display_name	Oncology
topics[0].display_name	HER2/EGFR in Cancer Research
topics[1].id	https://openalex.org/T11752
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9785000085830688
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	Cancer Treatment and Pharmacology
topics[2].id	https://openalex.org/T11016
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9771999716758728
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2741
topics[2].subfield.display_name	Radiology, Nuclear Medicine and Imaging
topics[2].display_name	Monoclonal and Polyclonal Antibodies Research
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2777329042
concepts[0].level	5
concepts[0].score	0.9514344930648804
concepts[0].wikidata	https://www.wikidata.org/wiki/Q420323
concepts[0].display_name	Lapatinib
concepts[1].id	https://openalex.org/C2779786085
concepts[1].level	4
concepts[1].score	0.9409929513931274
concepts[1].wikidata	https://www.wikidata.org/wiki/Q412616
concepts[1].display_name	Trastuzumab
concepts[2].id	https://openalex.org/C530470458
concepts[2].level	3
concepts[2].score	0.5587906837463379
concepts[2].wikidata	https://www.wikidata.org/wiki/Q128581
concepts[2].display_name	Breast cancer
concepts[3].id	https://openalex.org/C502942594
concepts[3].level	1
concepts[3].score	0.5459588170051575
concepts[3].wikidata	https://www.wikidata.org/wiki/Q3421914
concepts[3].display_name	Cancer research
concepts[4].id	https://openalex.org/C62112901
concepts[4].level	2
concepts[4].score	0.44077885150909424
concepts[4].wikidata	https://www.wikidata.org/wiki/Q189159
concepts[4].display_name	Cell growth
concepts[5].id	https://openalex.org/C2994372470
concepts[5].level	4
concepts[5].score	0.4351911246776581
concepts[5].wikidata	https://www.wikidata.org/wiki/Q4118072
concepts[5].display_name	Cancer cell lines
concepts[6].id	https://openalex.org/C98274493
concepts[6].level	1
concepts[6].score	0.43261483311653137
concepts[6].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[6].display_name	Pharmacology
concepts[7].id	https://openalex.org/C185592680
concepts[7].level	0
concepts[7].score	0.4206872284412384
concepts[7].wikidata	https://www.wikidata.org/wiki/Q2329
concepts[7].display_name	Chemistry
concepts[8].id	https://openalex.org/C121608353
concepts[8].level	2
concepts[8].score	0.3447592258453369
concepts[8].wikidata	https://www.wikidata.org/wiki/Q12078
concepts[8].display_name	Cancer
concepts[9].id	https://openalex.org/C71924100
concepts[9].level	0
concepts[9].score	0.33447036147117615
concepts[9].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[9].display_name	Medicine
concepts[10].id	https://openalex.org/C126322002
concepts[10].level	1
concepts[10].score	0.2799886167049408
concepts[10].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[10].display_name	Internal medicine
concepts[11].id	https://openalex.org/C96232424
concepts[11].level	3
concepts[11].score	0.19913136959075928
concepts[11].wikidata	https://www.wikidata.org/wiki/Q4118072
concepts[11].display_name	Cancer cell
concepts[12].id	https://openalex.org/C55493867
concepts[12].level	1
concepts[12].score	0.09192773699760437
concepts[12].wikidata	https://www.wikidata.org/wiki/Q7094
concepts[12].display_name	Biochemistry
keywords[0].id	https://openalex.org/keywords/lapatinib
keywords[0].score	0.9514344930648804
keywords[0].display_name	Lapatinib
keywords[1].id	https://openalex.org/keywords/trastuzumab
keywords[1].score	0.9409929513931274
keywords[1].display_name	Trastuzumab
keywords[2].id	https://openalex.org/keywords/breast-cancer
keywords[2].score	0.5587906837463379
keywords[2].display_name	Breast cancer
keywords[3].id	https://openalex.org/keywords/cancer-research
keywords[3].score	0.5459588170051575
keywords[3].display_name	Cancer research
keywords[4].id	https://openalex.org/keywords/cell-growth
keywords[4].score	0.44077885150909424
keywords[4].display_name	Cell growth
keywords[5].id	https://openalex.org/keywords/cancer-cell-lines
keywords[5].score	0.4351911246776581
keywords[5].display_name	Cancer cell lines
keywords[6].id	https://openalex.org/keywords/pharmacology
keywords[6].score	0.43261483311653137
keywords[6].display_name	Pharmacology
keywords[7].id	https://openalex.org/keywords/chemistry
keywords[7].score	0.4206872284412384
keywords[7].display_name	Chemistry
keywords[8].id	https://openalex.org/keywords/cancer
keywords[8].score	0.3447592258453369
keywords[8].display_name	Cancer
keywords[9].id	https://openalex.org/keywords/medicine
keywords[9].score	0.33447036147117615
keywords[9].display_name	Medicine
keywords[10].id	https://openalex.org/keywords/internal-medicine
keywords[10].score	0.2799886167049408
keywords[10].display_name	Internal medicine
keywords[11].id	https://openalex.org/keywords/cancer-cell
keywords[11].score	0.19913136959075928
keywords[11].display_name	Cancer cell
keywords[12].id	https://openalex.org/keywords/biochemistry
keywords[12].score	0.09192773699760437
keywords[12].display_name	Biochemistry
language	en
locations[0].id	doi:10.1158/1535-7163.22499191.v1
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/1535-7163.22499191.v1
locations[1].id	pmh:oai:figshare.com:article/22499191
locations[1].is_oa	True
locations[1].source.id	https://openalex.org/S4306400572
locations[1].source.issn
locations[1].source.type	repository
locations[1].source.is_oa	False
locations[1].source.issn_l
locations[1].source.is_core	False
locations[1].source.is_in_doaj	False
locations[1].source.display_name	OPAL (Open@LaTrobe) (La Trobe University)
locations[1].source.host_organization	https://openalex.org/I196829312
locations[1].source.host_organization_name	La Trobe University
locations[1].source.host_organization_lineage	https://openalex.org/I196829312
locations[1].license	cc-by
locations[1].pdf_url
locations[1].version	submittedVersion
locations[1].raw_type	Text
locations[1].license_id	https://openalex.org/licenses/cc-by
locations[1].is_accepted	False
locations[1].is_published	False
locations[1].raw_source_name
locations[1].landing_page_url	https://figshare.com/articles/journal_contribution/Supplementary_Methods_from_Dacomitinib_PF-00299804_an_Irreversible_Pan-HER_Inhibitor_Inhibits_Proliferation_of_HER2-Amplified_Breast_Cancer_Cell_Lines_Resistant_to_Trastuzumab_and_Lapatinib/22499191
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5054528392
authorships[0].author.orcid	https://orcid.org/0000-0002-3821-6603
authorships[0].author.display_name	Ondrej Kalous
authorships[0].author_position	first
authorships[0].raw_author_name	Ondrej Kalous
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5045387212
authorships[1].author.orcid	https://orcid.org/0000-0003-4708-0071
authorships[1].author.display_name	Dylan Conklin
authorships[1].author_position	middle
authorships[1].raw_author_name	Dylan Conklin
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5009971985
authorships[2].author.orcid
authorships[2].author.display_name	Amrita Desai
authorships[2].author_position	middle
authorships[2].raw_author_name	Amrita J. Desai
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5028010756
authorships[3].author.orcid	https://orcid.org/0000-0001-7408-1091
authorships[3].author.display_name	Neil A. O’Brien
authorships[3].author_position	middle
authorships[3].raw_author_name	Neil A. O'Brien
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5104110850
authorships[4].author.orcid
authorships[4].author.display_name	Charles Ginther
authorships[4].author_position	middle
authorships[4].raw_author_name	Charles Ginther
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5049155681
authorships[5].author.orcid
authorships[5].author.display_name	Lee G. Anderson
authorships[5].author_position	middle
authorships[5].raw_author_name	Lee Anderson
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5114257754
authorships[6].author.orcid
authorships[6].author.display_name	David J. Cohen
authorships[6].author_position	middle
authorships[6].raw_author_name	David J. Cohen
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5052493398
authorships[7].author.orcid
authorships[7].author.display_name	Carolyn D. Britten
authorships[7].author_position	middle
authorships[7].raw_author_name	Carolyn D. Britten
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5073680362
authorships[8].author.orcid	https://orcid.org/0000-0001-5040-0772
authorships[8].author.display_name	Ian Taylor
authorships[8].author_position	middle
authorships[8].raw_author_name	Ian Taylor
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5074923974
authorships[9].author.orcid	https://orcid.org/0000-0003-1835-0335
authorships[9].author.display_name	James G. Christensen
authorships[9].author_position	middle
authorships[9].raw_author_name	James G. Christensen
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5015491002
authorships[10].author.orcid	https://orcid.org/0000-0002-6330-498X
authorships[10].author.display_name	Dennis J. Slamon
authorships[10].author_position	middle
authorships[10].raw_author_name	Dennis J. Slamon
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5073989429
authorships[11].author.orcid	https://orcid.org/0000-0003-2494-2126
authorships[11].author.display_name	Richard S. Finn
authorships[11].author_position	last
authorships[11].raw_author_name	Richard S. Finn
authorships[11].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/1535-7163.22499191.v1
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Supplementary Methods from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T10755
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9957000017166138
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2730
primary_topic.subfield.display_name	Oncology
primary_topic.display_name	HER2/EGFR in Cancer Research
related_works	https://openalex.org/W2089223283, https://openalex.org/W2266153359, https://openalex.org/W2161139034, https://openalex.org/W3013826160, https://openalex.org/W4362533893, https://openalex.org/W4362611355, https://openalex.org/W4362533990, https://openalex.org/W4362533815, https://openalex.org/W4362611338, https://openalex.org/W4362611346
cited_by_count	0
locations_count	2
best_oa_location.id	doi:10.1158/1535-7163.22499191.v1
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/1535-7163.22499191.v1
primary_location.id	doi:10.1158/1535-7163.22499191.v1
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/1535-7163.22499191.v1
publication_date	2023-04-03
publication_year	2023
referenced_works_count	0
abstract_inverted_index.file,	1
abstract_inverted_index.<p>PDF	0
abstract_inverted_index.55K.</p>	2
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	12
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.6100000143051147
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.26796523
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False